Your money resources during COVID-19 and beyond: explained.

You and your money have options right now. Getty Images

Now may be a time of uncertainty, but you shouldn't have to also worry about the availability and security of your money. Texas Citizens Bank is always available to answer questions — COVID-19-related and otherwise — and has laid out some options for those wondering what sort of financial resources are available.

SBA loan
Cash flow is a business' life blood. The Small Business Administration is working with local banks to offer helpful business resources during this challenging time.

The Paycheck Protection Program provides small businesses — including independent contractors and the self-employed — with the funds to pay up to eight weeks of payroll costs, including benefits. Funds can also be used to pay interest on mortgages, rent, and utilities.

Those interested in applying for a Paycheck Protection Program loan through the SBA are encouraged to apply through their current financial institution as that will likely be the quickest route to receiving funding.

Loan payments will also be deferred for six months. No collateral or personal guarantees are required, and neither the government nor lenders will charge small businesses any fees. For more information about PPP, head here.

The SBA also offers low-interest disaster recovery loans to help businesses and homeowners recover from declared disasters. They can be used for both physical damage repairs and economic injury, the latter up to $2 million in assistance for businesses and nonprofits to help overcome their temporary loss of revenue.

Accounts receivable purchase solution
Accounts receivable purchase solution provides cash upfront for your invoices. TCB will check your customer's creditworthiness and, once approved, the bank will purchase one or more accounts receivable from that customer. You get the majority (usually 80 percent) of your AR amount upfront and accrue daily fee (for example, if you get paid the next day, you're only charged for one day). Once your customer pays the AR, TCB pays you the remaining balance, minus a small fee.

TCB's AR purchase solution ranges from $10,000-$1 million and doesn't have a long-term contract, allowing you the flexibility to pick and choose which invoices you'd like to sell to the bank. Find out more about how Accounts Receivable Purchase Solution works here.

How to bank from home
Most banks offer online banking and mobile apps with the following features:

  • Mobile check deposit — deposit checks simply by taking a photo of them using your mobile banking app
  • Online bill pay — pay your internet, electricity, gas, and other recurring bills online or through the app
  • Account summary — check your account balance and view your recent transactions
  • Some apps, like the Texas Citizens Bank app, offer additional services like budgeting, spending alerts, and peer-to-peer payment services, so you can quickly and securely monitor your spending and pay a friend or family member

Lastly, be on the lookout for financial scams. Fraudsters and scam artists tend to take advantage of uncertain times like these. Email, text, and phone scams are rampant, so please be careful to check that all communication you receive is truly from your bank. If you are unsure of a communication's validity, don't respond or giveaway any personal information. Always contact your bank directly to check.

Trending News

Building Houston

 
 

InformAI has three AI-based products geared at improving health care. Photo via Getty Images

In Houston, we’re lucky to have top-tier doctors in the Texas Medical Center, ready to treat us with the newest technology. But what about our family members who have to rely on rural hospitals? Thanks to one Houston company, doctors in smaller community hospitals may soon have new tools at their disposal that could improve outcomes for patients around the world.

Since InnovationMap last caught up with Jim Havelka, CEO of InformAI, two years ago, that hope has come far closer to a reality. InformAI is a VC-backed digital health company. Part of JLABS @ TMC innovation facilities, the company uses artificial intelligence to develop both diagnostic tools and clinical outcome predictors. And two of the company’s products will undergo FDA regulatory testing this year.

SinusAI, which helps to detect sinus-related diseases in CT scans, received its CE Mark — the European equivalent of FDA approval — last year and is being sold across the Atlantic today, says Havelka. He adds that in the United States alone, there are roughly 700,000 sinus surgeries that the product is positioned to support.

Another product, RadOnc-AI, is designed to help doctors prescribe radiation dose plans for head and neck cancers.

“Ideally the perfect plan would be to provide radiation to the tumor and nothing around it,” says Havelka. “We’ve built a product, RadOnc-AI, which autogenerates the dose treatment plan based on medical images of that patient.”

It can be an hours-long process for doctors to figure out the path and dose of radiation themselves, but the new product “can build that initial pass in about five minutes,” Havelka says.

That in itself is an exciting development, but because this technology was developed using the expertise of some of the world’s top oncologists, “the first pass plan is in line with what [patients would] get at tier-one institutions,” explains Havelka. This creates “tremendous equity” among patients who can afford to travel to major facilities and those that can’t.

To that end, RadOnc-AI was recently awarded a $1.55 million grant from the Cancer Prevention and Research Institute of Texas, or CPRIT, a state agency that funds cancer research. The Radiological Society of North America announced late last year that InformAI was named an Aunt Minnie Best of Radiology Finalist.

“It’s quite prestigious for our company,” says Havelka. Other recent laurels include InformAI being named one of the 10 most promising companies by the Texas Life Science Forum in November.

And InformAI is only gaining steam. A third product is earlier in its stage of development. TransplantAI will optimize donor organ and patient recipient matches.

“A lot of organs are harvested and discarded,” Havelka says.

His AI product has been trained on a million donor transplants to help determine who is the best recipient for an organ. It even takes urgency into account, based on a patient’s expected mortality within 90 days. The product is currently a fully functional prototype and will soon move through its initial regulatory clearances.

The company — currently backed by three VC funds, including DEFTA Partners, Delight Ventures, and Joyance Partners — is planning to do another seed round in Q2 of 2023.

“We’ve been able to get recognized for digital health products that can be taken to market globally,” says Havelka.

But what he says he’s most excited about is the social impact of his products. With more money raised, InformAI will be able to speed up development of additional products, including expanding the cancers that the company will be targeting. And with that, more and more patients will one day be treated with the highest level of care.

Trending News